Literature DB >> 27610560

Probing the Diversity of T Cell Dysfunction in Cancer.

Ryan T Sowell1, Susan M Kaech2.   

Abstract

T cell dysfunction in cancer comes in many forms, with two new varieties reported in this issue. Daley et al. find that T cells expressing γδ T cell receptors (TCR) promote pancreatic tumor growth by inhibiting activation of T cells with conventional TCRs. Singer et al. characterize dysfunctional tumor infiltrating lymphocytes to reveal a role for zinc homeostasis in anti-tumor immunity.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27610560      PMCID： PMC5523106          DOI： 10.1016/j.cell.2016.08.058

Source DB:  PubMed          Journal:  Cell        ISSN： 0092-8674            Impact factor:   41.582


  10 in total

1.  Interleukin-27 priming of T cells controls IL-17 production in trans via induction of the ligand PD-L1.

Authors:  Kiyoshi Hirahara; Kamran Ghoreschi; Xiang-Ping Yang; Hayato Takahashi; Arian Laurence; Golnaz Vahedi; Giuseppe Sciumè; Aisling O'Hara Hall; Christopher D Dupont; Loise M Francisco; Qian Chen; Masao Tanaka; Yuka Kanno; Hong-Wei Sun; Arlene H Sharpe; Christopher A Hunter; John J O'Shea
Journal:  Immunity       Date:  2012-06-21       Impact factor: 31.745

2.  Stable inhibitory activity of regulatory T cells requires the transcription factor Helios.

Authors:  Hye-Jung Kim; R Anthony Barnitz; Taras Kreslavsky; Flavian D Brown; Howell Moffett; Madeleine E Lemieux; Yasemin Kaygusuz; Torsten Meissner; Tobias A W Holderried; Susan Chan; Philippe Kastner; W Nicholas Haining; Harvey Cantor
Journal:  Science       Date:  2015-10-16       Impact factor: 47.728

3.  γδ T Cells Support Pancreatic Oncogenesis by Restraining αβ T Cell Activation.

Authors:  Donnele Daley; Constantinos Pantelis Zambirinis; Lena Seifert; Neha Akkad; Navyatha Mohan; Gregor Werba; Rocky Barilla; Alejandro Torres-Hernandez; Mautin Hundeyin; Vishnu Raj Kumar Mani; Antonina Avanzi; Daniel Tippens; Rajkishen Narayanan; Jung-Eun Jang; Elliot Newman; Venu Gopal Pillarisetty; Michael Loran Dustin; Dafna Bar-Sagi; Cristina Hajdu; George Miller
Journal:  Cell       Date:  2016-08-25       Impact factor: 41.582

4.  Purinergic agonist induction of metallothionein.

Authors:  X Xiong; S H Garrett; K Arizono; F O Brady
Journal:  Proc Soc Exp Biol Med       Date:  1992-10

5.  Emerging concepts of T cell metabolism as a target of immunotherapy.

Authors:  Chih-Hao Chang; Erika L Pearce
Journal:  Nat Immunol       Date:  2016-04       Impact factor: 25.606

6.  Hypoxia-inducible factors enhance the effector responses of CD8(+) T cells to persistent antigen.

Authors:  Andrew L Doedens; Anthony T Phan; Martin H Stradner; Jessica K Fujimoto; Jessica V Nguyen; Edward Yang; Randall S Johnson; Ananda W Goldrath
Journal:  Nat Immunol       Date:  2013-09-29       Impact factor: 25.606

7.  Transcription factor T-bet represses expression of the inhibitory receptor PD-1 and sustains virus-specific CD8+ T cell responses during chronic infection.

Authors:  Charlly Kao; Kenneth J Oestreich; Michael A Paley; Alison Crawford; Jill M Angelosanto; Mohammed-Alkhatim A Ali; Andrew M Intlekofer; Jeremy M Boss; Steven L Reiner; Amy S Weinmann; E John Wherry
Journal:  Nat Immunol       Date:  2011-05-29       Impact factor: 25.606

8.  Prostaglandin E2 and programmed cell death 1 signaling coordinately impair CTL function and survival during chronic viral infection.

Authors:  Jonathan H Chen; Curtis J Perry; Yao-Chen Tsui; Matthew M Staron; Ian A Parish; Claudia X Dominguez; Daniel W Rosenberg; Susan M Kaech
Journal:  Nat Med       Date:  2015-03-23       Impact factor: 53.440

9.  A Distinct Gene Module for Dysfunction Uncoupled from Activation in Tumor-Infiltrating T Cells.

Authors:  Meromit Singer; Chao Wang; Le Cong; Nemanja D Marjanovic; Monika S Kowalczyk; Huiyuan Zhang; Jackson Nyman; Kaori Sakuishi; Sema Kurtulus; David Gennert; Junrong Xia; John Y H Kwon; James Nevin; Rebecca H Herbst; Itai Yanai; Orit Rozenblatt-Rosen; Vijay K Kuchroo; Aviv Regev; Ana C Anderson
Journal:  Cell       Date:  2016-09-08       Impact factor: 41.582

10.  Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity.

Authors:  Santiago Zelenay; Annemarthe G van der Veen; Jan P Böttcher; Kathryn J Snelgrove; Neil Rogers; Sophie E Acton; Probir Chakravarty; Maria Romina Girotti; Richard Marais; Sergio A Quezada; Erik Sahai; Caetano Reis e Sousa
Journal:  Cell       Date:  2015-09-03       Impact factor: 41.582
  10 in total
  11 in total

Review 1.  Gene editing to enhance the efficacy of cancer cell therapies.

Authors:  Tara Murty; Crystal L Mackall
Journal:  Mol Ther       Date:  2021-10-18       Impact factor: 11.454

2.  High Expression of IKZF2 in Malignant T Cells Promotes Disease Progression in Cutaneous T Cell Lymphoma.

Authors:  Bufang Xu; Fengjie Liu; Yumei Gao; Jingru Sun; Yingyi Li; Yuchieh Lin; Xiangjun Liu; Yujie Wen; Shengguo Yi; Jingyang Dang; Ping Tu; Yang Wang
Journal:  Acta Derm Venereol       Date:  2021-12-07       Impact factor: 3.875

3.  CRISPR Screening of CAR T Cells and Cancer Stem Cells Reveals Critical Dependencies for Cell-Based Therapies.

Authors:  Dongrui Wang; Briana C Prager; Christine E Brown; Jeremy N Rich; Ryan C Gimple; Brenda Aguilar; Darya Alizadeh; Hongzhen Tang; Deguan Lv; Renate Starr; Alfonso Brito; Qiulian Wu; Leo J Y Kim; Zhixin Qiu; Peng Lin; Michael H Lorenzini; Behnam Badie; Stephen J Forman; Qi Xie
Journal:  Cancer Discov       Date:  2020-12-16       Impact factor: 39.397

4.  Increased expression of adenosine 2A receptors in metastatic renal cell carcinoma is associated with poorer response to anti-vascular endothelial growth factor agents and anti-PD-1/Anti-CTLA4 antibodies and shorter survival.

Authors:  Takao Kamai; Toshiki Kijima; Toyonori Tsuzuki; Akinori Nukui; Hideyuki Abe; Kyoko Arai; Ken-Ichiro Yoshida
Journal:  Cancer Immunol Immunother       Date:  2021-01-08       Impact factor: 6.968

5.  Impaired CD27+IgD+ B Cells With Altered Gene Signature in Rheumatoid Arthritis.

Authors:  Fanlei Hu; Wei Zhang; Lianjie Shi; Xu Liu; Yuan Jia; Liling Xu; Huaqun Zhu; Yingni Li; Dakang Xu; Liwei Lu; Xiaoyan Qiu; Wanli Liu; Junjie Qiao; Yongfu Wang; Zhanguo Li
Journal:  Front Immunol       Date:  2018-03-23       Impact factor: 7.561

6.  The Dysfunctional Immune System in Common Variable Immunodeficiency Increases the Susceptibility to Gastric Cancer.

Authors:  Irene Gullo; Catarina Costa; Susana L Silva; Cristina Ferreira; Adriana Motta; Sara P Silva; Rúben Duarte Ferreira; Pedro Rosmaninho; Emília Faria; José Torres da Costa; Rita Câmara; Gilza Gonçalves; João Santos-Antunes; Carla Oliveira; José C Machado; Fátima Carneiro; Ana E Sousa
Journal:  Cells       Date:  2020-06-19       Impact factor: 6.600

Review 7.  Nanocarriers for pancreatic cancer imaging, treatments, and immunotherapies.

Authors:  Luman Liu; Prakash G Kshirsagar; Shailendra K Gautam; Mansi Gulati; Emad I Wafa; John C Christiansen; Brianna M White; Surya K Mallapragada; Michael J Wannemuehler; Sushil Kumar; Joyce C Solheim; Surinder K Batra; Aliasger K Salem; Balaji Narasimhan; Maneesh Jain
Journal:  Theranostics       Date:  2022-01-01       Impact factor: 11.600

8.  Divergent fates of antigen-specific CD8+ T cell clones in mice with acute leukemia.

Authors:  Xiufen Chen; Brendan W MacNabb; Blake Flood; Bruce R Blazar; Justin Kline
Journal:  Cell Rep       Date:  2021-11-09       Impact factor: 9.995

9.  Organoids with cancer stem cell-like properties secrete exosomes and HSP90 in a 3D nanoenvironment.

Authors:  Takanori Eguchi; Chiharu Sogawa; Yuka Okusha; Kenta Uchibe; Ryosuke Iinuma; Kisho Ono; Keisuke Nakano; Jun Murakami; Manabu Itoh; Kazuya Arai; Toshifumi Fujiwara; Yuri Namba; Yoshiki Murata; Kazumi Ohyama; Manami Shimomura; Hirohiko Okamura; Masaharu Takigawa; Tetsuya Nakatsura; Ken-Ichi Kozaki; Kuniaki Okamoto; Stuart K Calderwood
Journal:  PLoS One       Date:  2018-02-07       Impact factor: 3.240

Review 10.  Targeting Tumor Microenvironment by Small-Molecule Inhibitors.

Authors:  Shangwei Zhong; Ji-Hak Jeong; Zhikang Chen; Zihua Chen; Jun-Li Luo
Journal:  Transl Oncol       Date:  2019-11-27       Impact factor: 4.243
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.